Month: March 2023

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Written by Customer Service on March 15, 2023. Posted in Public Companies.

CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. The Company will be presenting four posters regarding its lead program, QN-302, and one poster regarding an in-vivo study...

Star Equity Holdings, Inc. Announces 2022 Fourth Quarter and Full Year Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Q4 2022 revenues and gross profit increased 8.8% and 34.8%, respectively, compared to Q4 2021 Q4 2022 net income increased to $1.9 million from $4.4 million loss in Q4 2021 Q4 2022 adjusted EBITDA increased to $3.1 million from $1.0 million in Q4 2021 OLD GREENWICH, Conn., March 15, 2023 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star Equity” or the “Company”), a diversified holding company, reported today its financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2022. All 2022 and 2021 amounts in this release are unaudited. Following the sale of a portion of our Healthcare business in early 2021, all financial results for the 2022 and 2021 reporting periods, unless stated otherwise, relate to continuing operations, which include the Healthcare, Construction, and Investments...

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Initiated U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC); initial results are expected in the first half of 2024Initiated U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) and dosed the first patient; initial results expected in the third quarter of 2023 Presented results of the Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers Symposium Completed enrollment of the Phase 1 monotherapy arm of CTX-471 (CD137 agonistic antibody) and initiated enrollment in the combination arm of CTX-471 with KEYTRUDA® (pembrolizumab) in patients with select solid tumors; initial combination results are expected in the second half of 2023 Completed GMP manufacturing and toxicology studies of CTX-8371...

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update. “We made considerable progress in 2022, including the filing and acceptance of two new INDs for our next generation CDK4/6 inhibitor and our first-in-class, highly selective SMARCA2 degrader. Our current clinical pipeline consists of four differentiated and internally...

Blink Charging Unveils Completely Redesigned Mobile EV Charger for Fleets and EV Driver Roadside Assistance

Written by Customer Service on March 15, 2023. Posted in Public Companies.

Faster, lighter, quieter, and more cost effective than before, Blink’s new portable EV charger provides EV fleets with range confidence and creates new service offering for roadside assistance providers Miami Beach, FL, March 15, 2023 (GLOBE NEWSWIRE) — Blink Charging Co. (Nasdaq: BLNK) (“Blink” or the “Company”), a leading owner and operator of electric vehicle (EV) charging equipment and services, today announced the immediate availability of its redesigned Blink mobile charger. The freestanding charger is built to provide emergency charging for stranded electric vehicles, directly addressing the needs of EV fleet operators, roadside assistance providers, insurance companies, auto manufacturers, and public roadway assistance programs. The Blink mobile charger is rated at 32 amps and charges an EV with up to 0.5 to 1 mile of range...

Progressive Reports February 2023 Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, March 15, 2023 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for February 2023: February(millions, except per share amounts and ratios; unaudited) 2023 2022 ChangeNet premiums written $ 6,057.8 $ 4,625.7 31 %Net premiums earned $ 4,166.6 $ 3,626.1 15 %Net income $ 150.3 $ 61.6 144 %Per share available to common shareholders $ 0.25 $ 0.10 149 %Total pretax net realized gains (losses) on securities $ (117.1 ) $ (209.4 ) (44)%Combined ratio 95.1 93.7 1.4 pts.Average diluted equivalent common shares 587.0 586.3 0 % February(thousands; unaudited) 2023 2022 ChangePolicies in Force Personal Lines Agency – auto 8,039.7 7,805.6 3...

Form 8.3 – [EMIS GROUP PLC 14 03 2023] – (CGWL)

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [DEVRO PLC 14 03 2023] – (CGWL)

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree DEVRO PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (OTCPK:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the “LOI”) with Worksite Labs, Inc. (“WSL”), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the “Proposed Transaction”). “We believe the proposed merger could enhance shareholder value and strengthen the company’s operating performance,” commented...

Grafana Labs Acquires Pyroscope, the Company Behind the Popular Open Source Continuous Profiling Project

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

The open source projects Grafana Phlare and Pyroscope will be merged under the name Grafana Pyroscope NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) — Grafana Labs, the company behind the world’s most ubiquitous open and composable operational dashboards, today announced that it has acquired Pyroscope, the company that created the popular open source continuous profiling project of the same name. With this acquisition, Grafana Phlare, the open source continuous profiling database that Grafana Labs launched last year, and the Pyroscope project will be merged under the new name Grafana Pyroscope. Continuous profiling has been dubbed the fourth pillar of observability (after metrics, logs, and traces). It offers developers a deeper view of resource usage of their code, allowing them to understand their application performance and optimize...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals